| Name | Title | Contact Details |
|---|---|---|
Jon Smith |
Head of Transversal Global Alignment, Process R&D | Profile |
Tyler Miyawaki |
R&D Chief of Staff | Profile |
Tim Alefantis |
R&D Global Project Head, Senior Director, Pre to Early Development Project Leader | Profile |
Warny Michael |
Director, External R&D | Profile |
Maria Thummaluru |
Director, R&D SQO | Profile |
Vapotherm Inc., is a publicly held corporation based in Exeter, New Hampshire that was founded in 1999 as a medical device manufacturer after creating the first heated and humidified high flow therapy nasal cannula system.
Cirrus Pharmaceuticals is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Oryzon’s MISSION is to identify and manipulate biomarkers -genes and proteins- allowing the development of new therapeutic tools in the quest to improve human health – covering unmet clinical needs- and in benefits for our shareholders. Oryzon’s VISION is to become a world leader company in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics` Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.